Welcome to our dedicated page for Stryker SEC filings (Ticker: SYK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Stryker Corporation filings document the regulatory record of a New York Stock Exchange-listed medical technology issuer with operations in MedSurg, Neurotechnology and Orthopaedics. Its 8-K reports cover operating results, financial-condition updates, material events, Regulation FD disclosures and exhibits tied to company press releases.
The filing record also describes governance and capital-structure matters, including definitive proxy materials, annual-meeting votes, director elections, auditor ratification, executive-compensation votes, common stock and listed senior unsecured notes. Recent material-event filings include cybersecurity incident disclosures and amendments describing operational and reporting updates connected to Stryker's information technology environment.
Stryker Corporation reported that William E. Berry, Jr., its Vice President and Chief Accounting Officer, will retire from that role effective September 1, 2026. Emily Baculik, currently Vice President, Corporate Controller, will become chief accounting officer on the same date.
Berry will serve as Advisor to the Chief Financial Officer from September 1, 2026 through August 15, 2027, receiving his current annual base salary of $510,000 and remaining eligible for a 2026 incentive bonus targeted at 50% of salary. Baculik’s annual base salary will increase to $420,000, with a bonus target of 45% of salary and a proposed February 2027 long‑term incentive grant valued at about $400,000 split between stock options and restricted stock units.
Stryker Corporation VP and Chief HR Officer M. Kathryn Fink reported a mix of stock option exercises, tax withholding, and open-market sales of Stryker common stock. On May 8, 2026, she exercised employee stock options to acquire 21,582 shares at exercise prices of $179.3500 and $154.1400 per share. On the same date, 16,362 shares were disposed of to satisfy tax obligations, which is recorded as a tax-withholding disposition rather than a market sale.
On May 11, 2026, 3,500 shares were sold in the open market at an average price of $283.4530 per share by the 2023 Mary Fink Living Trust, and 5,220 shares were sold directly at an average price of $283.8450 per share. After these transactions, Fink holds 13,137 shares directly, 444 shares indirectly through a 401(k), and 177 shares indirectly via the Living Trust, which includes 128 shares acquired under Stryker’s Employee Stock Purchase Plan as of March 31, 2026.
Stryker Corporation reported solid first-quarter 2026 results with net sales of $6.02 billion, up from $5.87 billion a year earlier, driven mainly by MedSurg and Neurotechnology growth. Net earnings rose to $745 million, and diluted EPS increased to $1.93.
Adjusted diluted EPS was $2.60, down 8.5% from 2025 as adjusted operating margin contracted to 21.1%. A March 11, 2026 cybersecurity incident caused idle production time, pressuring gross margin to 63.3% and segment margins, though manufacturing operations and commercial systems have been restored. Cash from operations improved to $581 million, while the company repaid $1.0 billion of maturing notes and ended the quarter with $2.97 billion in cash and marketable securities.
Suri Rajeev reported acquisition or exercise transactions in this Form 4 filing.
Stryker Corporation director Rajeev Suri received an equity award in the form of restricted stock units. On May 6, 2026, he was granted 762 RSUs that were reported as common stock, with no cash paid as this is compensation rather than a market purchase.
The RSUs will vest in full on the earlier of the company’s 2027 Annual Meeting of Shareholders or May 6, 2027. Each RSU represents a contingent right to receive one share of Stryker common stock. Following this grant, Suri directly owns 7,190 shares of Stryker common stock.
Stryker Corporation director Ronda E. Stryker received an equity award of 762 Restricted Stock Units (RSUs) of Stryker common stock. The award is compensation, not an open-market purchase, and increases her directly held shares to 1,322 after the grant.
The RSUs vest in full on the earlier of the company’s 2027 Annual Meeting of Shareholders or May 6, 2027, and each RSU converts into one share of common stock upon settlement. In addition to her direct holdings, she has significant indirect ownership through various trusts, including 37,600 shares held by the 1988 William D. Johnston Trust, 12,857,163 shares held by the L. Lee Stryker Trust, and 2,231,173 shares held by a revocable trust.
Skeete Tatum Lisa M reported acquisition or exercise transactions in this Form 4 filing.
Stryker Corporation director Lisa M. Skeete Tatum received an equity grant in the form of Restricted Stock Units (RSUs). She was awarded 762 shares of common stock at no stated purchase price, increasing her direct holdings to 5,205 shares after the grant.
The 762 RSUs vest in full on the earlier of the 2027 Annual Meeting of Shareholders of Stryker Corporation or May 6, 2027. Each RSU represents a contingent right to receive one share of Stryker common stock upon vesting, aligning a portion of the director’s compensation with future company performance and share price.